文献速递中毒与环境急症消化、代谢与肾脏急症

阿片受体激动剂治疗与阿片过量公共卫生紧急状态期间死亡风险:基于人群的回顾性队列研究

Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.
PubMed 文献 · BMJ · 2020-03-31
一句话结论在非法芬太尼流行背景下,阿片使用障碍患者接受阿片受体激动剂治疗(OAT)期间全因死亡率标准化死亡比显著低于脱离治疗期间,且OAT的保护效应随芬太尼流行而增强。

该研究基于加拿大不列颠哥伦比亚省五个健康行政数据库的个体级链接,纳入1996年1月1日至2018年9月30日期间接受OAT的55 347例阿片使用障碍患者,比较接受与未接受OAT期间的死亡风险。随访期间7030例(12.7%)死亡。接受OAT期间全因标准化死亡比为4.6(95%CI 4.4–4.8),未接受OAT期间为9.7(95%CI 9.5–10.0)。在芬太尼流行期,未接受OAT相对于接受OAT的死亡相对风险从芬太尼引入前的2.1倍(95%CI 1.8–2.4)升至研究期末的3.4倍(95%CI 2.8–4.3),相对风险增加65%。结论认为OAT留存与死亡率显著降低相关,随着芬太尼等合成阿片在非法毒品供应中普及,OAT对死亡的保护效应增强,而脱离OAT期间死亡风险仍高。

要点

  • 接受OAT期间全因标准化死亡比为4.6(95%CI 4.4–4.8),未接受OAT期间为9.7(95%CI 9.5–10.0)。
  • 在芬太尼流行期,未接受OAT相对于接受OAT的死亡相对风险从芬太尼引入前的2.1倍(95%CI 1.8–2.4)升至研究期末的3.4倍(95%CI 2.8–4.3),相对风险增加65%。
  • 55 347例接受OAT的阿片使用障碍患者中,随访期间7030例(12.7%)死亡。
  • OAT对死亡的保护效应随芬太尼及其他合成阿片在非法毒品供应中普及而增强,而脱离OAT期间死亡风险仍高。
  • 作者认为,随着芬太尼在全球范围扩大,应重视提高OAT留存率并防止接受者停止治疗的干预措施。

适用人群与场景

  • 1996年1月1日至2018年9月30日期间接受OAT的阿片使用障碍患者55 347例,数据来自加拿大不列颠哥伦比亚省五个健康行政数据库的个体级链接。

研究设计与关键结果

  • 研究类型为基于人群的回顾性队列研究,样本量55 347例,数据来自加拿大不列颠哥伦比亚省五个健康行政数据库的个体级链接,人群为1996年1月1日至2018年9月30日期间接受OAT的阿片使用障碍患者。
  • 主要结局:随访期间7030例(12.7%)死亡;接受OAT期间全因标准化死亡比为4.6(95%CI 4.4–4.8),未接受OAT期间为9.7(95%CI 9.5–10.0)。
  • 在芬太尼流行期,未接受OAT相对于接受OAT的死亡相对风险在芬太尼引入前为2.1倍(95%CI 1.8–2.4),研究期末升至3.4倍(95%CI 2.8–4.3),相对风险增加65%。
  • 按治疗状态(接受OAT、未接受OAT)、开始和停止治疗后的时间(1、2、3–4、5–12、>12周)以及药物类型(美沙酮、丁丙诺啡/纳洛酮)计算死亡风险。

证据类型、等级与局限

  • 证据类型:基于人群的回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,随着芬太尼在全球范围扩大,应重视提高OAT留存率并防止接受者停止治疗的干预措施。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To compare the risk of mortality among people with opioid use disorder on and off opioid agonist treatment (OAT) in a setting with a high prevalence of illicitly manufactured fentanyl and other potent synthetic opioids in the illicit drug supply.

DESIGN: Population based retrospective cohort study.

SETTING: Individual level linkage of five health administrative datasets capturing drug dispensations, hospital admissions, physician billing records, ambulatory care reports, and deaths in British Columbia, Canada.

PARTICIPANTS: 55 347 people with opioid use disorder who received OAT between 1 January 1996 and 30 September 2018.

MAIN OUTCOME MEASURES: All cause and cause specific crude mortality rates (per 1000 person years) to determine absolute risk of mortality and all cause age and sex standardised mortality ratios to determine relative risk of mortality compared with the general population. Mortality risk was calculated according to treatment status (on OAT, off OAT), time since starting and stopping treatment (1, 2, 3-4, 5-12, >12 weeks), and medication type (methadone, buprenorphine/naloxone). Adjusted risk ratios compared the relative risk of mortality on and off OAT over time as fentanyl became more prevalent in the illicit drug supply.

RESULTS: 7030 (12.7%) of 55 347 OAT recipients died during follow-up. The all cause standardised mortality ratio was substantially lower on OAT (4.6, 95% confidence interval 4.4 to 4.8) than off OAT (9.7, 9.5 to 10.0). In a period of increasing prevalence of fentanyl, the relative risk of mortality off OAT was 2.1 (95% confidence interval 1.8 to 2.4) times higher than on OAT before the introduction of fentanyl, increasing to 3.4 (2.8 to 4.3) at the end of the study period (65% increase in relative risk).

CONCLUSIONS: Retention on OAT is associated with substantial reductions in the risk of mortality for people with opioid use disorder. The protective effect of OAT on mortality increased as fentanyl and other synthetic opioids became common in the illicit drug supply, whereas the risk of mortality remained high off OAT. As fentanyl becomes more widespread globally, these findings highlight the importance of interventions that improve retention on opioid agonist treatment and prevent recipients from stopping treatment.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Pearce LA, Min JE, Piske M, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ. 2020. PMID: 32234712. doi:10.1136/bmj.m772

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。